ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+102.07%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$346M
AUM Growth
+$346M
(+68%)
Cap. Flow
+$58.9M
Cap. Flow
% of AUM
17.01%
Top 10 Holdings %
Top 10 Hldgs %
48.64%
Holding
51
New
19
Increased
11
Reduced
14
Closed
5
Top Buys
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$19.3M |
| 2 |
Celldex Therapeutics
CLDX
|
$13M |
| 3 |
ADAP
Adaptimmune Therapeutics
ADAP
|
$11.7M |
| 4 |
Kura Oncology
KURA
|
$11M |
| 5 |
Immunovant
IMVT
|
$8.52M |
Top Sells
| 1 |
Axsome Therapeutics
AXSM
|
$18M |
| 2 |
Aurinia Pharmaceuticals
AUPH
|
$11.2M |
| 3 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$7.45M |
| 4 |
Larimar Therapeutics
LRMR
|
$7.02M |
| 5 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$5.53M |
Sector Composition
| 1 | Healthcare | 91.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Adverum Biotechnologies
ADVM
$64.6M
| $36.5M | 10.54% | 1,746,500 +42,000 | +2% | +$877K |
|
|
IMMU
2
DELISTED
Immunomedics Inc
IMMU
| $19.3M | 5.58% | +545,000 | New | +$19.3M |
|
3
BioXcel Therapeutics
BTAI
$59M
| $18.1M | 5.22% | 340,500 +25,500 | +8% | +$1.35M |
|
4
Iovance Biotherapeutics
IOVA
$807M
| $16.2M | 4.68% | 590,000 +190,500 | +48% | +$5.23M |
|
5
Mersana Therapeutics
MRSN
$36.5M
| $14.8M | 4.28% | 632,500 -195,000 | -24% | -$4.56M |
|
|
6
Kura Oncology
KURA
$686M
| $14.2M | 4.11% | 872,500 +674,500 | +341% | +$11M |
|
|
AVDL
7
Avadel Pharmaceuticals
AVDL
$1.43B
| $14.2M | 4.09% | 1,752,218 -921,500 | -34% | -$7.45M |
|
|
8
Celldex Therapeutics
CLDX
$1.47B
| $13M | 3.76% | +1,000,000 | New | +$13M |
|
|
ADAP
9
Adaptimmune Therapeutics
ADAP
$15.6M
| $11.7M | 3.37% | +1,165,000 | New | +$11.7M |
|
10
Relmada Therapeutics
RLMD
$37.2M
| $10.5M | 3.03% | 234,500 +143,550 | +158% | +$6.42M |
|
|
11
Larimar Therapeutics
LRMR
$310M
| $10.3M | 2.97% | 823,169 -562,831 | -41% | -$7.02M |
|
12
BioCryst Pharmaceuticals
BCRX
$1.74B
| $9.05M | 2.62% | 1,900,000 +1,650,000 | +660% | +$7.86M |
|
13
Gyre Therapeutics
GYRE
$703M
| $8.79M | 2.54% | 1,497,900 +113,300 | +8% | +$665K |
|
|
KRTX
14
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $8.69M | 2.51% | 78,000 +22,000 | +39% | +$2.45M |
|
|
15
Immunovant
IMVT
$2.56B
| $8.52M | 2.46% | +350,000 | New | +$8.52M |
|
16
Ascendis Pharma
ASND
$11.8B
| $8.21M | 2.37% | 55,500 -7,700 | -12% | -$1.14M |
|
|
BLU
17
DELISTED
BELLUS Health Inc.
BLU
| $7.87M | 2.27% | 765,000 -305,000 | -29% | -$3.14M |
|
|
18
Axsome Therapeutics
AXSM
$6.05B
| $7.41M | 2.14% | 90,000 -218,500 | -71% | -$18M |
|
19
Merus
MRUS
$4.98B
| $7.4M | 2.14% | +460,000 | New | +$7.4M |
|
20
Cartesian Therapeutics
RNAC
$261M
| $6.71M | 1.94% | 2,364,204 | – | – |
|
21
Applied Therapeutics
APLT
$71M
| $6.58M | 1.9% | 182,000 +80,000 | +78% | +$2.89M |
|
|
KDMN
22
DELISTED
Kadmon Holdings, Inc.
KDMN
| $6.55M | 1.89% | 1,280,000 -1,080,000 | -46% | -$5.53M |
|
23
Xenon Pharmaceuticals
XENE
$2.98B
| $6.49M | 1.87% | 517,500 -111,000 | -18% | -$1.39M |
|
24
Apellis Pharmaceuticals
APLS
$3.48B
| $6.21M | 1.79% | 190,000 -19,500 | -9% | -$637K |
|
|
LSACU
25
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
| $6.16M | 1.78% | 560,000 | – | – |
|